Official UK procurement notice
NHS National Framework Agreement for the Supply of products for the management of Hereditary Angioedema
Authority: NHS England (Central government)·Consortium: 2 public authorities
Re-procurement plannedNHS National Framework for the supply and treatment of Blood Disorders · tender expected
What is being bought14 lots · detail below
Published requirement descriptionNational Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for a list of the purchasing points.
CPV: Blood products · Pharmaceutical products · Plasma extracts
How this framework works
From the published notice- Bids received
- 2 bids received · 10 suppliers appointed
- Framework period
- 1 yr 6 mo from 1 Jul 2022
Lots and requirements (14)Procurement structure
14 lots · 7 with a published value · same evaluation weights on every lotEvery one of these 7 lots carries the same published figure, £1: it is the framework's maximum for the whole notice, not each lot's own budget, and no share per lot is published. The cards below say ceiling above rather than repeat it.
Lot #1C1 Esterase – Recombinant IV (acute treatment)CancelledLot estimate not published
NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.<br/><br/>Additional CPV Codes:<br/>33141520 – Plasma Extracts<br/>33141510 – Blood Products
Lot #2C1 Esterase – Plasma derived IV (acute treatment)CancelledLot estimate not published
NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.<br/><br/>Additional CPV Codes:<br/>33141520 – Plasma Extracts<br/>33141510 – Blood Products
Lot #3C1 Esterase – Plasma derived IV (prophylaxis treatment)AwardedLot estimate not published
NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.<br/><br/>Additional CPV Codes:<br/>33141520 – Plasma Extracts<br/>33141510 – Blood Products
Lot #4C1 Esterase – Plasma derived Subcut (prophylaxis treatment)AwardedLot estimate not published
NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.<br/><br/>Additional CPV Codes:<br/>33141520 – Plasma Extracts<br/>33141510 – Blood Products
Lot #5IcatibantAwardedLot estimate not published
NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.<br/><br/>Additional CPV Codes:<br/>33141520 – Plasma Extracts<br/>33141510 – Blood Products
Lot #6LanadelumabAwardedLot estimate not published
NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.<br/><br/>Additional CPV Codes:<br/>33141520 – Plasma Extracts<br/>33141510 – Blood Products
Lot #7BerotralstatAwardedLot estimate not published
NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.<br/><br/>Additional CPV Codes:<br/>33141520 – Plasma Extracts<br/>33141510 – Blood Products
Lot #8C1 Esterase – Recombinant IV (acute treatment)ceiling above
NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
Lot #9C1 Esterase – Plasma derived IV (acute treatment)ceiling above
NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
Lot #10C1 Esterase – Plasma derived IV (prophylaxis treatment)ceiling above
NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
Lot #11C1 Esterase – Plasma derived Subcut (prophylaxis treatment)ceiling above
NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
Lot #12Icatibantceiling above
NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
Lot #13Lanadelumabceiling above
NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
Lot #14Berotralstatceiling above
NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
What it takes to wini
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
Evaluation split and conditions of participation as published; the tender pack may add morei
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
Published sub-criteria (3)
- Security of Supply: 20%
- Ease of Use: 10%
- price: 70%
Published award criteria (3)
- Security of Supply: 20%
- Ease of Use: 10%
- Price: 70%
- Price carries 70 of 100 points: a 10% discount moves about 7 points. This one is won on the number: sharpen the price before polishing the prose.
- “NHS National Framework Agreement for the Supply of products for the…” is a framework: the contest is a place on its panel, not a single contract.
Price arithmetic assumes straight proportional scoring; the tender pack may use another formula.
Procedure terms & legal framework
From the official record · publisher note attached- Procedure method
- Open procedure
- Legal basis
- CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
- Procurement category
- Goods
- Notice status
- Awarded
- Procurement threshold
- Unspecified in notice
- Regulatory regime
- Standard
- Commercial structure
- Framework agreement
- Who may use this agreement
- Not stated in the notice; call-off rights may be limited to the establishing authority
- Competition type
- Competitive procedure
- GPA / WTO covered
- Yes (GPA)
- Recurring procurement
- No (one-off requirement)
- First published
- 8 Feb 2022, 15:38 GMT
- Last source update
- 21 Jul 2022, 11:44 BST
- Award evaluation window
- 16 Mar 2022 – …
- Authority reference
CM/PHS/19/5583- FTS notice number
2022/S 000-019862- Classification (CPV)
- Delivery area
- Official registry OCID
ocds-h6vhtk-0314adFind a Tender
- Electronic trading
- e-invoicing allowed · electronic ordering · electronic payment
Publisher note: RESPONDING TO THIS NOTICE:<br/>Any supplier may be disqualified who does not respond to the following in the requisite manner:<br/>1) Submission of expression of interest and procurement specific information<br/>This procurement exercise will be conducted on the eTendering portal at<br/>https://healthfamily.force.com/s/Welcome<br/>Candidates wishing to be considered for this procurement exercise must register, and provide additional procurement specific information (if requested) through the eTendering portal as follows:<br/>1.1) If not already registered,Candidates should register on the eTendering portal at<br/>https://health-family.force.com/s/Welcome and click the link to register:<br/>- agree to the user agreement<br/>- populate company details<br/>1.2) Once registered, candidates must register interest as follows:<br/>- log to the portal<br/>- select "Find Opportunities" from the supplier home screen, use the "Sort by:" facility to find this opportunity and select the bold blue title to select<br/>review opportunity details and click "Register Interest"<br/>- as you select the opportunity, you can review documents, send clarification messages,submit the response or decline to respond (if<br/>you decide not to participate in the opportunity)<br/>1.3) There is a supplier user guide on using the system and Candidates can contact the Atamis help desk at [email protected] or by calling 0800 9956035 for technical assistance when completing responses.<br/>2) General supplier information.<br/>To manage and assess supplier information the Contracting Authority requests candidates provide their company profile in the Government's Supplier Registration Service (which has replaced sid4gov), as follows:<br/>2.1) If not already registered (the previous sid4gov password, login and details will still be on the system), candidates must go to the following web page<br/>https://supplierregistration.cabinetoffice.gov.uk and select "Register" at the top of the page. Key in details as requested to search for your company. If you do not have a D-U-N-S®Number, click on the link at the right of the page to obtain a number from D&B.<br/>Candidates must obtain a Dun & Bradstreet(D&B) D-U-N-S® Number to enable registration on the system.<br/>2.2) Once registration is complete you are able to create and update your company profile. Candidates should ensure all the mandatory fields of their profile are completed and up to date for each procurement exercise.<br/>D&B data will be supplied automatically by D&B.<br/>2.3) For further help or information concerning this telephone +44 (0) 161 413 7982 or via the message function on the website.<br/>OTHER CONTRACTING AUTHORITIES<br/>The framework agreement is for the benefit of other participating NHS bodies (whether acting individually, or on behalf of, or together as members of any consortia) along with any other non-NHS bodies which the participants deem necessary for the delivery of services or<br/>goods to NHS bodies, local authorities, other government departments or non-departmental public bodies charged with the delivery of healthcare<br/>or health related services.
How it was run
Official noticeTender documents are also served through a separate tool: http://health.atamis.co.uk ↗
- Appointment period ends
- 16 Mar 2022, 13:00 GMT
- Submission channel
- {"electronicSubmission","written"}
- Accepted languages
- en
- Bids opened
- 16 Mar 2022, 13:00 GMT
Timeline
16 Mar 2022 → 21 Jul 2022 · 5 dates- Admission / appointment period endsperiod end, not a bid countdown16 Mar 2022, 13:00 GMT
- Bids opened16 Mar 2022, 13:00 GMT
- Bids must remain valid until14 Jun 2022, 23:59 BST
- Contract starts1 Jul 2022, 00:00 BST
- Notice published21 Jul 2022, 11:44 BST
Notice history
2 events · 3 releases on Find a Tender · since 19 Jul 2022- Status changed to complete19 Jul 2022, 17:19 BST
- Buyer details updated19 Jul 2022, 17:19 BST
Published amendments (1 · 0 deadline changes)
| When | What | Before | After | Shift |
|---|---|---|---|---|
| — | TextNUTS code · I.1.5 | UKE | UK |
1 amendment published without a description.
Commercial outcome & contract awards
Published awards, contracts and bid statistics, not a forecast14 suppliers are admitted to this framework without individual award values or dates, see the supplier list below.
Contracts
All 14 of these contracts carry the same published figure, £1, the framework's maximum for the whole notice, not each contract's own value. They are not eleven separate sums.
Hereditary Angioedema. Lot 1 - C1 Esterase – Recombinant IV (acute treatment)
- Signed
- 20 Jun 2022
- Value
- ceiling above
- Status
- active
Hereditary Angioedema. Lot 5 - Icatibant
- Signed
- 20 Jun 2022
- Value
- ceiling above
- Status
- active
Hereditary Angioedema. Lot 5 - Icatibant
- Signed
- 20 Jun 2022
- Value
- ceiling above
- Status
- active
Hereditary Angioedema. Lot 5 - Icatibant
- Signed
- 20 Jun 2022
- Value
- ceiling above
- Status
- active
Hereditary Angioedema. Lot 5 - Icatibant
- Signed
- 20 Jun 2022
- Value
- ceiling above
- Status
- active
Hereditary Angioedema. Lot 5 - Icatibant
- Signed
- 20 Jun 2022
- Value
- ceiling above
- Status
- active
Lot 3 - C1 Esterase – Plasma derived IV (prophylaxis treatment)
- Signed
- 20 Jun 2022
- Value
- ceiling above
- Status
- active
Hereditary Angioedema. Lot 6 - Lanadelumab
- Signed
- 20 Jun 2022
- Value
- ceiling above
- Status
- active
Hereditary Angioedema. Lot 7 - Berotralstat
- Signed
- 20 Jun 2022
- Value
- ceiling above
- Status
- active
Hereditary Angioedema. Lot 2 - C1 Esterase – Plasma derived IV (acute treatment)
- Signed
- 20 Jun 2022
- Value
- ceiling above
- Status
- active
Hereditary Angioedema. Lot 2 - C1 Esterase – Plasma derived IV (acute treatment)
- Signed
- 20 Jun 2022
- Value
- ceiling above
- Status
- active
Lot 4 - C1 Esterase – Plasma derived Subcut (prophylaxis treatment)
- Signed
- 20 Jun 2022
- Value
- ceiling above
- Status
- active
Hereditary Angioedema. Lot 5 - Icatibant
- Signed
- 20 Jun 2022
- Value
- ceiling above
- Status
- active
Hereditary Angioedema. Lot 5 - Icatibant
- Signed
- 20 Jun 2022
- Value
- ceiling above
- Status
- active
Bid statistics published by the authority
| Lot | Bids | SME | VCSE | Valid bid range |
|---|---|---|---|---|
| 3 · C1 Esterase – Plasma derived IV (prophylaxis treatment) | 1bids · 1 electronic · 1 from abroad | 0 | — | — |
| 4 · C1 Esterase – Plasma derived Subcut (prophylaxis treatment) | 1bids · 1 electronic · 1 from abroad | 0 | — | — |
| 5 · Icatibant | 10bids · 10 electronic · 10 from abroad | 4 | — | — |
| 6 · Lanadelumab | 1bids · 1 electronic · 1 from abroad | 0 | — | — |
| 7 · Berotralstat | 1bids · 1 electronic · 1 from abroad | 1 | — | — |
| Whole notice | 2bids · 2 electronic · 2 from abroad | 0 | — | — |
Contracting authority & participating public bodies
2 public bodies on the noticeConsortium members and other public bodies
- The NHS Commissioning Board (operating under the name of NHS England)Contracting authorityMinistry or any other national or federal authority, including their regional or local subdivisionsHealth
Dispute resolution & review bodies
- The High CourtReview body
Framework contractors & participating bidders
10 commercial parties on the notice- Accord-UK LtdFramework contractor
- BioCryst Ireland LimitedFramework contractor
- CSL Behring UK LtdFramework contractor
- Celix Pharma Ltd.Framework contractor
- CiplaFramework contractor
- Martindale PharmaFramework contractor
- Pharming GroupFramework contractor
- Piramal Critical care LimitedFramework contractor
- Takeda UK LtdFramework contractor
- Wockhardt UK LimitedFramework contractor
Official documents & specifications (2)
Official links; attachments are not copiedTender pack and attachments
- Economic and financial selection criteria
- Technical selection criteria